Assembly biosciences nominates development candidate abi-6250, an orally bioavailable hdv entry inhibitor

− abi-6250 demonstrated low nanomolar potency against hepatitis d virus and selective inhibition of ntcp in preclinical studies with once-daily dosing projected –
ASMB Ratings Summary
ASMB Quant Ranking